Evaluation criteria | N = 11 |
Study design | |
1) Description of the setting (dates, period of enrolment) | 9 (82%) |
2) Inclusion and exclusion criteria were described | 11 (100%) |
3) Justification explained for the selected study population size | 7 (64%) |
4) Details of the interventions (pharmacological or non-pharmacological treatment), to allow replication | 11 (100%) |
5) Details on efficacy assessment were described | 11 (100%) |
6) Statistical methods were clearly described | 10 (91%) |
7) Randomised trial | 7 (64%) |
8) Multicentric study | 4 (36%) |
Neuropathy-related | |
9) Neuropathy assessment criteria described (NCI-CTCAE criteria or neuropathy questionnaire) | 10 (91%) |
10) A neuropathy exam was performed | 2 (18%) |
11) Neurophysiological testing was performed | 0 (0%) |
12) Chronic CIPN was defined or implied | 4 (36%) |
Study population | |
13) The clinical variables “age”, “sex” and “cancer disease” was described | 9 (82%) |
14) Inclusion of patients undergoing exclusively to oxaliplatin-based ChT | 3 (27%) |
15) Oxaliplatin regimen and cumulative dose were described | 1 (9%) |
Results | |
16) Number of patients reported at each group or subgroup (eligible, included, analysed) | 10 (91%) |
17) Number of patients undergoing oxaliplatin-based ChT | 7 (64%) |
18) Description objectively response in CIPN relief | 9 (82%) |
19) Addressed limitations and potential sources of bias | 7 (64%) |